Clene will soon meet with the Food and Drug Administration to discuss analyses that could support an application for ...

PRESS RELEASE MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

Kolar Toyota ALS Fishing Tournament at the end of May includes a panel to talk about hopeful advancements in research.

ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...

Precision Care Medicine students work with clinical faculty at Johns Hopkins Medicine to learn how to use machine learning ...

Home > Press release: Study launched to identify new ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...